NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies Meeting Abstract

  

Authors:	Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; Siddiqi, T.; Wang, M. L.; Sun, C.; Abdel-Wahab, O.; Schwab, A.; Tan, M.; Meredith, E.; Gessner, M. A.; Kim, S. Y.; Wiestner, A.; Danilov, A. V.
Abstract Title:	NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies
Meeting Title:	64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	140
Issue:	Suppl. 1
Meeting Dates:	2022 Dec 10-13
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2022-11-15
Start Page:	2329
End Page:	2332
Language:	English
ACCESSION:	WOS:000893223202140
DOI:	10.1182/blood-2022-164772
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/205021